INTRODUCTION

CD8
+ cytotoxic T lymphocytes (CTLs) are thought to play an important role in elimination of hepatitis C virus (HCV), while also contributing to pathogenesis in this infection (Chisari, 1997; Cerny & Chisari, 1999; Rehermann & Chisari, 2000) . Virus-specific CTLs recognize viral antigens on the infected cells in a human leukocyte antigen (HLA) class I molecule-restricted manner, then lysing the cells (Gotch et al., 1987; Cannon et al., 1988) . Although reports concerning HCV-specific CTL epitopes are accumulating (Ward et al., 2002) , which epitopes are most active in viral clearance or immunopathogenesis in vivo remains to be determined. In HLA-B44-positive patients with chronic HCV infection, we previously demonstrated an inverse relationship between virus loads and peripheral blood CTL activities specific for HCV nucleoprotein amino acid residues 88-96 (Hiroishi et al., 1997) . Accordingly, the identification of new epitopes recognized by HCVspecific CTLs that play a role in elimination of HCV may suggest new ways to suppress growth of HCV and prevent persistent infection. A universally immunogenic vaccine against HCV infection would require multiple epitopes, preferably from conserved regions of HCV, with recognition by CTLs that is restricted by HLA molecules occurring commonly in the population to be immunized.
HLA-A24 is one of the most common HLA-A antigens in Asians (Chandanayingyong, 1986) , occurring in more than 60 % of Japanese (Date et al., 1996) . To study the immunopathogenesis of HCV infection in Japanese and other Asians and to develop HCV-specific CTL vaccines for these populations, identification of HCV-specific CTL epitopes with recognition restricted by HLA-A24 is therefore important. An HLA-A24 allele in Japanese people is almost exclusively HLA-A*2402 (Date et al., 1996 ). Yet few HLA-A*2402-restricted, HCV-specific CTL epitopes have been reported, in contrast to more numerous reports concerning HLA-A2.1-restricted, HCV-specific CTL epitopes (Ward et al., 2002) , representing the HLA most common in Caucasians.
A recently reported enzyme-linked immunospot (ELISpot) assay provides a rapid, inexpensive and efficient way to define a given HLA class I molecule-restricted, novel virusspecific CD8
+ T cell epitope and to characterize the breadth of CTL responses (Altfeld et al., 2000) . To identify HLA-A*2402-restricted, HCV-specific CD8
+ T cell epitopes, we synthesized 87 peptides derived from the total protein content of HCV and carrying HLA-A*2402-binding motifs (Ibe et al., 1996) and assessed the ability of the peptides to stimulate CD8 + T cells by counting interferon (IFN)-creleasing cells in HLA-A*2402-positive patients with acute or chronic hepatitis C using the ELISpot assay. Using the epitopes identified, we then studied the effects of treatment with IFN-a on frequencies of HCV-specific CD8 + T cells in two HLA-A*2402-positive patients with unresolved acute hepatitis C.
METHODS
Subjects. Three HLA-A*2402-positive patients with acute hepatitis C and eight with chronic hepatitis C, as well as two HLA-A*2402-negative patients with acute hepatitis C, were studied (Table 1) . As controls, one patient with acute hepatitis B, one with fatty liver and three healthy subjects with HLA-A24 were also studied. All hepatitis C patients had detectable HCV RNA in serum and had elevated serum concentrations of alanine aminotransferase (ALT). Diagnosis of chronic hepatitis was based on continuous elevation of serum ALT for more than 6 months. Diagnosis of acute hepatitis was based on acute clinical onset of hepatitis and confirmation of previously negative anti-HCV antibody. The study was approved by the Ethical Review Committees of Jichi Medical School and the Institute of Clinical Medicine of the University of Tsukuba. Informed consent was obtained from all subjects.
Synthetic peptide library. We synthesized 87 peptides of 8-11 amino acids in length that carried HLA-A*2402-binding motifs (tyrosine or phenylalanine at position 2 and leucine, isoleucine, phenylalanine or tryptophan at the C terminus; Ibe et al., 1996) . The peptides were based on the amino acid sequence of the genotype 1b HCV-J strain (accession no. D90208). Peptides were synthesized by and purchased from Mimotopes and were more than 80 % pure according to high-performance liquid chromatography. The peptides were grouped into 17 mixtures of five or six peptides each for experimental convenience (Mixtures A-Q; Table 2 ). Two previously reported HLA-A*2402-restricted CTL epitopes, HCV NS3 amino acid residues 1031-1039 (Kurokohchi et al., 2001 ) and 1100-1108 (Ito et al., 2001) were contained in mixture E.
Isolation of CD8
+ T cells and monocytes. Peripheral blood mononuclear cells (PBMC) were separated from heparinized peripheral blood by gradient centrifugation using Ficoll-Paque (Amersham Pharmacia Biotech). CD8 + T cells were isolated from PBMC by positive selection using antibody-conjugated magnetic + T cells and monocytes on flow cytometry were >95 % and >80 %, respectively.
ELISpot assay. Analysis of anti-peptide immune responses of peripheral blood CD8 + T cells was performed using an IFN-c-based ELISpot assay kit (Mabtech). Briefly, 10 5 CD8 + T cells, 10 4 monocytes as antigen-presenting cells and a peptide mixture or individual peptides at 10 mg ml 21 each were placed in duplicate in 96-well plates with a PVDF membrane at the bottom (MAIP S45; Millipore). Well bottoms were coated with anti-IFN-c monoclonal antibody (mAb). Cells were cultured for 40 h at 37 uC in a humidified 5 % CO 2 atmosphere. No peptide was added to the negative control wells. After culture, IFN-c spot-forming cells (SFCs) were visualized as described previously (Lalvani et al., 1997) . Responses were considered significant when a minimum of five SFCs were present per well, representing at least twice the number of SFCs in negative control wells. In preliminary studies, monocytes did not present IFN-c SFCs in response to stimulation with HCV peptides.
To enrich peptide-specific CD8 + T cells that might recognize a known HLA-A*2402-restricted epitope, 2610 6 PBMC pulsed with 10 mg peptide 1031-1039 ml 21 (Kurokohchi et al., 2001) were cultured in a 24-well flat-bottom plate for 9 days in RPMI 1640 medium supplemented with 10 % human serum AB blood type and 50 U recombinant human interleukin (rhIL)-2 ml 21 added on day 2. The cells were harvested after 9 days of culture and CD8 + T cells were isolated for an ELISpot assay.
Generation of HCV-specific CTLs. HCV-specific CTLs were generated as described previously (Hiroishi et al., 2002) . Briefly, PBMC were suspended at a cell density of 10 6 cells ml 21 in RPMI 1640 medium supplemented with 10 % human AB serum and a single peptide was added on day 0. Cells were incubated at 37 uC in a humidified 5 % CO 2 atmosphere. On day 2, rhIL-2 was added at a final concentration of 20 U ml
21
. On day 7, the culture was restimulated with the single peptide and irradiated autologous PBMC. Cytotoxic activity of peptide-induced effector cells was assessed on days 14-16. Crlabelled B-LCL were suspended in RPMI 1640 medium supplemented with 10 % fetal calf serum and incubated overnight at 37 uC with a synthetic peptide or infected with recombinant vaccinia virus (rVV) that endogenously expressed HCV antigens (K. Funatsuki & H. Ishiko, unpublished results). An m.o.i. of 5 was used for an 18 h incubation with rVV. Then, after incubating the effector cells with the target cells for 4 h at 37 uC in a humidified 5 % CO 2 atmosphere, supernatants were collected and radioactivity was measured with a gamma counter.
RESULTS
Screening of CD8
+ T cell epitopes by an ELISpot assay using the peptide mixtures When the isolated CD8 + T cells from 13 patients with HCV infection (subjects 1-13) were stimulated with peptide mixtures A-Q composed of HCV peptides with HLA-A*2402-binding motifs, eight of the 17 peptide mixtures elicited significant IFN-c SFC responses (Table 3) . Mixtures C and J each elicited responses from two patients' cells, but the other peptide mixtures each elicited responses in only one patient's cells. IFN-c SFC responses to the peptide mixtures were observed in cells from two of three HLA-A*2402-positive patients with acute hepatitis C, three of four with chronic hepatitis C lasting for less than 3 years and none of four with chronic hepatitis C for more than 10 years. In two of the five patients who demonstrated a NS4A 1672 -1682 , NS5A 2013 -2023 , NS5A 2089 -2099 , NS5B 2456 -2466 , NS5B 2613 -2623 Q NS5B 2694 -2704 , NS5B 2801 -2811 , NS5B 2833 -2843 , NS5B 2866 -2876 , NS5B 2973 -2983 positive IFN-c SFC response to peptide mixtures, a response was observed against more than one peptide mixture. Although peptide mixture E contained two previously reported HLA-A*2402-restricted CTL epitopes, it did not elicit an IFN-c SFC response from any patient's cells. Unexpectedly, one of two HLA-A*2402-negative patients with acute hepatitis C also demonstrated an IFN-c SFC response to one of the peptide mixtures. None of the control subjects (subjects 14-18) demonstrated a positive IFN-c SFC response to any peptide mixture.
Peptide specificity of HCV-specific CD8 + T cells
To identify the peptides that elicited IFN-c SFC responses, we assessed responses using isolated CD8 + T cells and the individual peptides making up the peptide mixture that had elicited the initial response. The following 11 peptides that elicited a significant IFN-c SFC response were identified: peptide 1375-1385 from mixture O in patient 1; peptide 790-798 from mixture C, peptide 2280-2288 from mixture G, peptide 284-293 from mixture H and peptides 1759-1768 and 1990-1999 from mixture K in patient 2; peptide 910-919 from mixture I and peptides 947-956 and 1243-1252 from mixture J in patient 4; peptide 1443-1452 from mixture J in patient 6; peptide 790-798 from mixture C in patient 7; peptide 2456-2466 from mixture P in patient 12 (data not shown). Peptide 790-798 elicited a response in both patients 2 and 7 who shared HLA-A*2402 and HLA-Cw*0801 molecules.
The magnitude of IFN-c SFC responses to single-peptide stimulation ranged from 4 to 139 SFC per 10 5 CD8 + T cells and summed frequencies of the SFCs in patients 2 and 4 were 146 and 193 SFC per 10 5 CD8 + T cells, respectively. Of the 11 peptides, two were 9-mers, seven were 10-mers and two were 11-mers. These epitopes were distributed throughout the entire HCV protein; one epitope was localized in each of the E1 and E2 regions, two in the NS2 region, three in the NS3 region, two in the NS4 region and three in the NS5 region. None of the 11 epitopes had been reported previously.
The individual peptides previously reported as HLA-A*2402-restricted, HCV-specific CTL epitopes did not elicit an ex vivo IFN-c SFC response in cells from any patient studied. The assay was repeated after CD8 + T cells were expanded by stimulating CD8 + T cells from patients 1 and 4 with the known HLA-A*2402-restricted, HCVspecific CTL epitope peptide 1031-1039 (Kurokohchi et al., 2001) for 9 days in the presence of rhIL-2 to enrich CD8 + T cells with specificity for the peptide. Although stimulation of the CD8 + T cells with the epitope peptides identified in the present study enriched peptide-specific CD8 + T cells, peptide 1031-1039-specific CD8 + T cells could not be enriched to attain a detectable level (Fig. 1) .
HLA restriction of peptide recognition
Using peptide-HLA-A*2402 dimer staining (Greten et al., 1998) , we examined whether recognition by CD8 + T cells of the epitope peptides identified was truly restricted by the HLA-A*2402 molecule. Although all 11 peptides effectively bound to HLA-A*2402 dimer proteins, only HCV NS5A peptide 2280-2288-HLA-A*2402 dimer complexes could stain CD8 + T cells of patient 2, indicating that recognition by CD8
+ T cells of the peptides other than the To define the HLA molecules that restricted recognition of peptides by CD8 + T cells other than peptide 2280-2288, we attempted to induce CTL lines by stimulating PBMC from patients with the individual peptides. We could generate CTLs specific for peptides 910-919, 947-956 and 1243-1252 from PBMC of patient 4 and CTLs specific for peptide 1443-1452 from PBMC of patient 6. The peptideinduced CTLs lysed not only peptide-pulsed autologous B-LCL but also B-LCL that had been infected with rVV, resulting in HCV protein expression including the peptide sequence in infected cells (data not shown). HLA restriction of peptide recognition by CTLs was studied using a panel of autologous and allogeneic B-LCL with known HLA haplotypes as target cells. CTLs induced by peptide 910-919 or 1243-1252 selectively lysed B-LCL expressing HLACw3 (HLA-Cw*0303 or HLA-Cw*0304 or both) that had been pulsed with the individual peptides ( Fig. 2a and b) , indicating that recognition of both HCV NS2 peptide 910-919 and NS3 peptide 1243-1252 was restricted by HLACw*0303 and HLA-Cw*0304 molecules. However, since the NS3 peptide 1243-1252-specific CTL lysis restricted by HLA-Cw*0303 and HLA-Cw*0304 was less than the total lysis for the peptide, the recognition of the peptide also might be restricted by HLA-B*4002 (Fig. 2b) . CTL induced by peptide 947-956 selectively lysed peptide-pulsed B-LCL expressing HLA-B61 (HLA-B*4002 or HLA-B*4006; Fig. 2c ) indicating that recognition of HCV NS2 peptide 947-956 was restricted by HLA-B*4002 and HLA-B*4006 molecules. CTL induced by peptide 1443-1452 selectively lysed peptide-pulsed B-LCL expressing HLA-A*0206 (Fig. 2d) , indicating that the recognition of the peptide 1443-1452 was restricted by an HLA-A*0206 molecule, although the possibility that the CTLs also could recognize the targets in an HLA-A*0207 molecule-restricted manner cannot be ruled out from the data in Fig. 2 
(d). CTLs induced by peptide 1443-1452 did not lyse peptide-pulsed B-LCL expressing HLA-A*0201 (data not shown).
Although we could not establish peptide-specific CTL lines, HCV E2 protein peptide 790-798 induced an IFN-c SFC response in cells from patients 2 and 7, who shared HLA class I alleles HLA-A*2402 and HLA-Cw*0801. Since peptide-HLA-A*2402 dimer complexes did not stain PBMC from patient 2 or 7 (H. Morita & M. Imawari, unpublished results), recognition of peptide 790-798 by CD8 + T cells is likely to be restricted by an HLA-Cw*0801 molecule. However, the possibility that HLA-A*2402 restricted the recognition of peptide 790-798 cannot be ruled out completely, since the dimer might not work efficiently.
Recognition of truncated and overlapping HCV peptides by CD8
+ T cells
To define further the epitopes within the peptides that elicited an IFN-c SFC response, truncated and overlapping peptides were synthesized and assayed for their ability to elicit a response from CD8 + T cells obtained from patients 4, 6 and 7 (Table 4) .
Peptide 1443-1452 truncated by 1 amino acid at its C terminus (peptide 1443-1451 or GFTGDFDSV by one-letter code) identified in patient 6 evoked 1?5 times as many IFN-c SFC as the original peptide, although the truncated peptide lost the HLA-A*2402-binding motif. Further truncation at the C terminus to produce peptide 1443-1450 or at the N terminus to produce peptide 1444-1452 led to loss of antigenicity. Thus, peptide 1443-1451 was defined as the minimal and optimal epitope for HCV-specific CD8 + T cells. The amino acid sequence of HCV NS3 protein residues 1443-1451 is well conserved among members of the same type and among different types of HCV except for the amino acid at position 1444, which can be either phenylalanine or tyrosine. HCV peptide 1443-1452 with tyrosine at position 1444 stimulated IFN-c production by CD8 + T cells from patient 6 as effectively as HCV peptide 1443-1452 with phenylalanine at position 1444 (data not shown).
Since both peptides 790-798 and 910-919 had an HLA-A*2402-binding amino acid residue at the position next to the C terminus, peptides with truncation of the HLA-A*2402-binding amino acid at the C terminus were synthesized and assayed for antigenicity. Neither of the truncated peptides retained antigenicity, indicating that C-terminal amino acids of peptides 790-798 and 910-919 were essential for antigenicity. The effect of truncation of the N-terminal amino acids was not studied. No studies of effects of truncation were performed for the other eight peptides.
HCV-specific CD8
+ T cell epitopes that were identified and their HLA restriction are shown in Table 5 .
Sequential analysis of HCV-specific CD8
+ T cell responses in two patients with unresolved acute hepatitis treated with IFN-a
To study the effects of IFN therapy on HCV-specific CD8 + T cell responses, we monitored changes in frequency of IFN-c-releasing CD8 + T cells in the peripheral bloods in patients 4 and 7 by ELISpot assay. The individual HCV epitope peptides were used to carry out assays during and after treatment with IFN-a or consensus IFN (Tong et al., 1997) (Fig. 3) . In both patients, frequencies of HCV peptide-specific, IFN-c-releasing CD8 + T cells in the peripheral blood decreased upon IFN therapy in association 910-919, 1243-1252 and 947-956 (from patient 4) and PBMC stimulated with peptide 1443-1452 (from patient 6) were assayed for cytotoxicity directed at autologous and allogeneic B-LCL of known HLA class I haplotypes that had been pulsed with the individual peptides. The effector-to-target ratio was 20. Specific cytotoxicity expressed as a percentage was calculated by subtracting cytotoxicity of effector cells to non-peptide-pulsed B-LCL from cytotoxicity to peptide-pulsed B-LCL. HLA molecules of CTLs and those shared by target cells are indicated at the top and bottom, respectively. ND, Not determined. DAmino acid(s) at the N terminus may be able to be truncated although the amino acid at the C terminus cannot be truncated. dDefined as minimal and optimal epitope.
with disappearance of serum HCV RNA and with ALT normalization. They were nearly undetectable at and after completion of therapy.
DISCUSSION
A proportion of patients with chronic HCV infection remain resistant to antiviral therapies including recently developed treatment modalities such as IFN-a2b plus ribavirin (Poynard et al., 1998) and pegylated IFN (Zeuzem et al., 2000) . Such treatment failure may be partly a reflection of insufficient antiviral immune responses. Augmentation of HCV-specific CD8 + CTL responses by therapeutic vaccines could enhance HCV elimination by IFN therapy, leading to a better treatment outcome. Development of a universally immunogenic vaccine would require identification of as many CTL epitopes as possible, especially those recognized by CTLs in association with common HLA class I molecules in the population.
In the present study, we sought to identify HCV-specific, CD8
+ T cell epitopes, with recognition restricted by HLA-A*2402, the most frequent HLA class I allele in Japanese and other Asians (Chandanayingyong, 1986) . We screened the epitopes by an ELISpot assay based on IFN-c release by
CD8
+ T cells obtained from HLA-A*2402-positive patients with acute or chronic hepatitis C in response to peptide stimulation. Eighty-seven peptides were synthesized based on HLA-A*2402-binding motifs and the amino acid sequence of type 1b HCV. We could identify 10 HCVspecific CTL epitopes that induced IFN-c release by CD8 + T cells from a total of five of seven HLA-A*2402-positive patients with acute or relatively early chronic hepatitis C but not in any of four patients with persisting chronic hepatitis. The findings indicate that the response of HCVspecific CTLs to the panel of peptides is very low in patients with prolonged HCV infection. Consistent with this interpretation, an HLA-B*3501-restricted CTL epitope peptide that induced strong HCV-specific CTL responses in peripheral blood cells in the acute phase of HCV infection reportedly failed to induce CTL responses in seven of seven patients with chronic hepatitis C (Ibe et al., 1998) . Frequencies of HLA-B*3501-restricted, HCV-specific CTL also have been reported to be very low in the peripheral blood of patients with chronic hepatitis C, although CTLs were detectable among the PBMC by flow cytometric analysis using HLA-B*3501 tetramers (Sobao et al., 2001) . In still other reports, frequencies (Lechner et al., 2000; Rehermann et al., 1996; He et al., 1999) and IFN-cproduction potential (Gruener et al., 2001 ; Wedemeyer et al., Unexpectedly, only one of the ten CTL epitopes identified in HLA-A*2402-positive patients was found to be definitely HLA-A*2402-restricted. In addition, the frequency of CD8 + T cells that responded to stimulation with the epitope was far less than for other CTL epitopes in this patient. The HLA class I molecules that restricted recognition of the other five epitopes by CD8 + T cells were thought to be HLA-Cw*0303 and HLA-Cw*0304 for two epitopes, HLA-B*4002 and HLA-B*4006 for one, HLA-A*0206 for one and probably HLA-Cw*0801 for another. The HLA class I molecules that restricted recognition of the remaining four epitopes by CD8 + T cells have not yet been defined. One more CD8
+ T cell epitope was identified using the peptides with HLA-A*2402-binding motifs in one of two HLA-A*2402-negative patients with acute hepatitis C, although the HLA class I molecule restricting recognition of the epitope has not been determined. In two of the six patients with positive CD8 + T cell responses the target epitopes were multiple and only one of the 11 peptides was targeted in more than one patient. These findings indicate that a universally immunogenic HLA-A*2402-restricted, HCVspecific CD8 + T cell epitope may not exist; epitopes with recognition by CD8 + T cells restricted by HLA molecules other than HLA-A*2402 presumably were contained in the synthetic peptides with HLA-A*2402-binding motifs. CTL responses to HCV infection are heterogeneous, as concluded by Lauer et al. (2002) .
We analysed sensitivity and specificity of previously reported HLA-A*2402-restricted, HCV-specific CTL epitopes (Kurokohchi et al., 2001; Ito et al., 2001) in HLA-A*2402-positive patients with acute and relatively recently acquired chronic hepatitis C. These two epitope peptides did not induce IFN-c SFC responses, suggesting that their immunogenicity might be low compared with other epitopes. However, HCV NS3 peptide 1031-1039 identified by Kurokohchi et al. (2001) has been reported to induce HCV-specific CTLs in three of four HLA-A*2402-positive patients with chronic hepatitis C. It has been reported that in vitro expansion of CD8 + T cells by stimulation with known HLA-A2-restricted CTL epitopes and culture in the presence of rhIL-2 revealed the existence of CD8 + T cells specific for the peptide, although IFN-c SFC responses ex vivo could not be induced . However, we could not confirm immunogenicity of the 1031-1039 epitope, even after stimulation and expansion with culture in the presence of rhIL-2. The limited number of patients in our study may have happened to lack CTLs responsive to stimulation with peptide 1031-1039; alternatively, the IFN-c-based ELISpot assay might detect a CD8
+ T cell population that is functionally different from the CTLs identified by Kurokohchi et al. (2001) . Consistent with this speculation, a 'stunned' CD8 + T cell population has been reported to emerge in the acute phase of HCV infection, retaining potent HCV-specific cytotoxicity but only limited capacity for IFN-c production (Lechner et al., 2000; Thimme et al., 2001) . CTLs responsive to the 1031-1039 peptide may belong to such a population.
Reliability of T cell epitope prediction based on HLAbinding motifs or algorithms (Rammensee et al., 1999) has been reported to be limited Anthony et al., 2002; Day et al., 2001) . Therefore, establishing that no immunodominant HLA-A*2402-restricted, HCVspecific CD8
+ T cell epitope exists would require screening HLA-A*2402-restricted, HCV-specific CD8 + T cell epitopes by an IFN-c ELISpot assay using overlapping peptides that span the entire HCV protein; such a study, in progress in our laboratory, may identify new HLA-A*2402-restricted, HCV-specific CD8 + T cell epitopes without known HLA-A*2402-binding motifs. This study is intended to define the hierarchy of immunodominance of CTL epitopes in patients with HCV infection. Lauer et al. (2002) demonstrated multiple unpredicted specificities of HCV-specific CD8 + T cell epitopes by an ELISpot assay using overlapping peptides that spanned the entire HCV protein, but none of the new epitopes that they found corresponded to those identified in the present study.
Using the CD8
+ T cell epitopes currently identified, we sequentially monitored frequencies of CD8 + T cells secreting IFN-c in response to stimulation with the epitope peptides during and after treatment of two patients with unresolved acute hepatitis C with IFN-a. Although effects of IFN-a therapy on HCV-specific CD8 + T cell responses have been reported from several laboratories (Löhr et al., 1999; Vertuani et al., 2002; Barnes et al., 2002) , results are conflicting. Löhr et al. (1999) have reported that augmentation of HLA class I-restricted tumour necrosis factor (TNF)-a responses by IFN-a therapy contributes to a better treatment outcome in patients with chronic hepatitis C. The decline of serum HCV RNA during IFN-a therapy has been described as having two phases: a rapid early phase, thought to reflect direct inhibition of HCV replication by IFN-a; and a slower second phase, thought to be mediated by cellular immune responses, especially those of CTLs (Neumann et al., 1998) . Augmentation of TNF-a-releasing HCV-specific CD8 + T cell responses by IFN-a may beneficially affect the second phase of HCV RNA decline. However, in our present study, numbers of HCV epitope peptide-sensitized CD8 + T cells in peripheral blood declined in parallel with decreases and disappearance of serum HCV RNA and with ALT normalization. The reason why our results differed from those of Löhr et al. (1999) is not known, but it could involve differences in degree of chronicity of disease, decrease rates of serum HCV RNA, doses of IFN-a or ethnicity of patients.
In conclusion, we have newly identified one definite HLA-A*2402-restricted, HCV-specific CD8 + T cell epitope and 10 probably non-HLA-A*2402-restricted epitopes by an IFN-c-based ELISpot assay using synthetic HCV peptides with HLA-A*2402-binding motifs. We could find HCVspecific CTL epitopes only in patients with acute or relatively early chronic hepatitis C. CD8 + T cell responses to HCV infection were heterogeneous. The findings indicate a need to identify as many HCV-specific CD8 + T cell epitopes as possible in large numbers of patients with acute or recently acquired chronic hepatitis C to understand better how immune responses eliminate HCV and contribute to pathogenesis. The ultimate aim is development of new strategies for enhancing immune responses for more effective control of HCV infection.
